Cargando…

Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Detalles Bibliográficos
Autores principales:	Rosario, D J, Bourke, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670490/ https://www.ncbi.nlm.nih.gov/pubmed/23632481 http://dx.doi.org/10.1038/bjc.2013.211

Ejemplares similares

Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
por: Bourke, L, et al.
Publicado: (2013)

Comment on ‘Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'
por: Shah, S I A, et al.
Publicado: (2013)

Reply: Performance indicators in ART: time for a reappraisal?
por: Vlaisavljevic, Veljko, et al.
Publicado: (2022)

Clinical Audit: Time for a Reappraisal?
por: Rigge, Marianne
Publicado: (1996)

Reply: Prostate Cancer and Cardiovascular Risk Factors
por: Klimis, Harry, et al.
Publicado: (2023)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Natura abhorret a vacuo. Future perspectives of autologous fibrin glue. Is it time for reappraisal?
por: Giammalva, Giuseppe R., et al.
Publicado: (2017)

Performance indicators in ART: time for a reappraisal?
por: Sbracia, Marco, et al.
Publicado: (2021)

Reply: ‘Hand pattern indicates risk of prostate cancer’
por: Rahman, A A, et al.
Publicado: (2011)

Reply: Calcium, dairy, and prostate cancer
por: Lee, I-M, et al.
Publicado: (2007)

Reply: benefits of screening cancer patients for distress still not demonstrated
por: Carlson, L E, et al.
Publicado: (2013)

The Costs and Benefits of Mindfulness and Reappraisal in Daily Life
por: Wenzel, Mario, et al.
Publicado: (2023)

Hormonal therapies and venous thrombosis: considerations for prevention and management—a reappraisal
por: Douxfils, Jonathan, et al.
Publicado: (2023)

Opisthorchiasis, hypercholesterolemia, and cholangiocarcinoma: A reappraisal
por: Joob, Beuy, et al.
Publicado: (2017)

Reply: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E
Publicado: (2007)

Yoga: An endocrine therapy
por: Kaduskar, Prashant, et al.
Publicado: (2015)

A reappraisal of corticosteroids use for COVID-19
por: Pati, Ilaria, et al.
Publicado: (2022)

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Temesgen, Zelalem, et al.
Publicado: (2021)

Reply to ‘Comment on “Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome”’
por: Berney, Daniel M
Publicado: (2017)

Cost-Effective Screening for Trichomoniasis—reply to Dr. Schwebke
por: Sorvillo, Frank, et al.
Publicado: (2002)

Human life cost in anaesthesiology cost-benefit decisions
por: Naftalovich, Rotem, et al.
Publicado: (2021)

Reply to Commentary on “Risk Factors for Transurethral Coagulation for Hemostasis During Holmium Laser Enucleation of the Prostate”
por: Yoon, Hyun Sik, et al.
Publicado: (2022)

Reply: Estimation of lead-time and overdiagnosis in breast cancer screening
por: Duffy, S W, et al.
Publicado: (2009)

Mental health insurance and attempted suicide: Need for a reappraisal
por: Sarkhel, Sujit
Publicado: (2021)

Reply: cost-effectiveness of population-based screening for colorectal cancer
por: Sharp, L, et al.
Publicado: (2013)

Reply: Gallstones, cholecystectomy, and the risk for developing pancreatic cancer
por: Bosetti, C, et al.
Publicado: (2003)

Reply: Cancer risk before and following organ transplantation
por: Adami, J
Publicado: (2004)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia - reply to the letter from Cohen, Peehl and Rosenfeld
por: Mantzoros, CS, et al.
Publicado: (1998)

Reply: Dietary acrylamide and cancer risk: additional data on coffee
por: Mucci, L A, et al.
Publicado: (2003)

Oral contraceptive (OC) use and risk of breast cancer - reply
por: Tryggvadóttir, L, et al.
Publicado: (1997)

Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer
por: Wong, C K E, et al.
Publicado: (2013)

Reply: Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort
por: Newton, R, et al.
Publicado: (2006)

Exposure history and molecular epidemiology of SARS-CoV-2: A reappraisal
por: Joob, Beuy, et al.
Publicado: (2023)

Reply: Is it time to rename hereditary cases of cerebral palsy?
por: Hu, Hao, et al.
Publicado: (2022)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Reply: Assessing health risks of complementary alternative medicines in cancer patients
por: Werneke, U, et al.
Publicado: (2004)

Self-Reported Adherence to Oral Endocrine Therapy among Breast Cancer Patients in Jordan
por: Faqeer, Nour, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ddo1usu98m8kn5e9ccd919ppe